Journal
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Volume 15, Issue 4, Pages 599-605Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737167.2015.1039518
Keywords
current reimbursement strategies; increasing treatment costs; oncology; patents and prizes; R&D costs
Ask authors/readers for more resources
The number of cancer therapies is increasing. Treatment costs, largely reflecting increasing prices, are also increasing. The regulatory process is increasing in intensity. Countries have initiated risk sharing agreements and/or special cancer funds to accommodate this expenditure growth. Given increasing pressures elsewhere on healthcare budgets, even this response is not sustainable. With many more cancer drugs in the pipeline and the prospects of combination therapy, it is unlikely that the existing policies being applied by payers can maintain budget constraints. Unless payers increase reimbursement and/or extend flexible reimbursement schemes, solutions will be required to ensure access to new cancer therapies - this includes looking at ways of reducing R&D costs. This perspective outlines the problems faced and suggests some solutions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available